Japan Lifeline Co., Ltd. (TYO:7575)

Japan flag Japan · Delayed Price · Currency is JPY
1,263.00
+3.00 (0.24%)
May 14, 2026, 3:30 PM JST
Market Cap88.68B -13.2%
Revenue (ttm)59.19B +4.6%
Net Income9.35B +0.4%
EPS133.28 +1.4%
Shares Out70.16M
PE Ratio9.48
Forward PE10.15
Dividend54.00 (4.24%)
Ex-Dividend DateMar 30, 2026
Volume213,100
Average Volume218,140
Open1,255.00
Previous Close1,260.00
Day's Range1,250.00 - 1,269.00
52-Week Range1,239.00 - 1,645.00
Betan/a
RSI27.85
Earnings DateMay 7, 2026

About Japan Lifeline

Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological ... [Read more]

Sector Healthcare
Founded 1981
Employees 1,250
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 7575
Full Company Profile

Financial Performance

In fiscal year 2026, Japan Lifeline's revenue was 59.19 billion, an increase of 4.55% compared to the previous year's 56.61 billion. Earnings were 9.35 billion, an increase of 0.35%.

Financial Statements

News

Japan Lifeline Earnings Call Transcript: Q4 2026

Record sales and profits were achieved, driven by strong core and new product growth, despite margin pressure from inflation and one-time costs. FY 2027 guidance anticipates continued top-line growth but lower profits due to higher investments and relocation expenses.

6 days ago - Transcripts

Q2 2026 Japan Lifeline Co Ltd Earnings Presentation (Japanese) Transcript

Q2 2026 Japan Lifeline Co Ltd Earnings Presentation (Japanese) Transcript

6 months ago - GuruFocus

Japan Lifeline Earnings Call Transcript: Q2 2026

Record H1 sales and profits were driven by strong core and new segment growth, despite headwinds from PFA adoption and price revisions. International expansion and a regenerative medicine partnership marked key developments.

7 months ago - Transcripts

Japan Lifeline Earnings Call Transcript: Q1 2026

Q1 FY2026 delivered 4.3% revenue and 2.4% operating profit growth, with net profit down 1.6% due to FX losses and asset disposals. Strong gains in neurovascular and GI segments offset CRM and PFA-related declines. Progress aligns with full-year guidance.

10 months ago - Transcripts